Zacks Investment Research downgraded shares of Advaxis (NASDAQ:ADXS) from a hold rating to a sell rating in a research report released on Monday, Zacks.com reports.

According to Zacks, “Advaxis, Inc. is a development stage biotechnology company focused on developing safe and effective cancer vaccines that utilize multiple mechanisms of immunity. The Company is developing a live Listeria vaccine technology under license from the University of Pennsylvania which secretes a protein sequence containing a tumor-specific antigen. The Company believes this vaccine technology is capable of stimulating the body’s immune system to process and recognize the antigen as if it were foreign, generating an immune response able to attack the cancer. It also considers this to be a broadly enabling platform technology that can be applied to the treatment of many types of cancers, infectious diseases and auto-immune disorders. The Company’s products in development include Lovaxin C and Lovaxin B, Lovaxin P. “

Other equities research analysts have also recently issued reports about the company. ValuEngine cut Zumiez from a hold rating to a sell rating in a report on Tuesday, July 2nd. HC Wainwright reiterated a neutral rating on shares of Aerpio Pharmaceuticals in a report on Wednesday, June 12th.

ADXS stock opened at $1.55 on Monday. Advaxis has a 12-month low of $1.50 and a 12-month high of $24.60. The business has a 50-day moving average price of $2.38.

A number of hedge funds have recently bought and sold shares of ADXS. Two Sigma Investments LP lifted its stake in Advaxis by 2,468.2% in the 4th quarter. Two Sigma Investments LP now owns 369,815 shares of the biotechnology company’s stock worth $70,000 after purchasing an additional 355,415 shares in the last quarter. BlackRock Inc. lifted its stake in Advaxis by 3.1% in the 4th quarter. BlackRock Inc. now owns 1,446,288 shares of the biotechnology company’s stock worth $275,000 after purchasing an additional 43,368 shares in the last quarter. Finally, Deutsche Bank AG lifted its stake in Advaxis by 5,970.3% in the 4th quarter. Deutsche Bank AG now owns 562,294 shares of the biotechnology company’s stock worth $106,000 after purchasing an additional 553,031 shares in the last quarter. Institutional investors own 24.40% of the company’s stock.

About Advaxis

Advaxis, Inc, a late-stage biotechnology company, focuses on the discovery, development, and commercialization of Listeria monocytogenes (Lm) technology based antigen delivery product in the United States. It is developing therapies for HPV-related cancers using axalimogene filolisbac (AXAL) for the treatment of head and neck cancer.

Recommended Story: How Does the Quiet Period Work?

Get a free copy of the Zacks research report on Advaxis (ADXS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Advaxis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Advaxis and related companies with MarketBeat.com's FREE daily email newsletter.